- $267.05m
- $172.61m
- $101.02m
Annual income statement for Carlsmed, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K |
| Standards: | USG | USG | USG |
| Status: | Final | Final | Final |
| Revenue | |||
| Total Revenue | 27.6 | 54.3 | 101 |
| Cost of Revenue | |||
| Gross Profit | 9.9 | 20 | 38 |
| Selling / General / Administrative Expenses | |||
| Research And Development | |||
| Total Operating Expenses | 64.7 | 103 | 162 |
| Operating Profit | -37.2 | -48.2 | -61.1 |
| Total Net Non Operating Interest Income / Expense | |||
| Other Net Non Operating Costs | |||
| Net Income Before Taxes | -37.8 | -48.5 | -59.3 |
| Provision for Income Taxes | |||
| Net Income After Taxes | -37.8 | -48.5 | -59.3 |
| Net Income Before Extraordinary Items | |||
| Net Income | -37.8 | -48.5 | -59.3 |
| Adjustments to Net Income | |||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||
| Income Available to Common Shareholders Including Extraordinary Items | |||
| Diluted Net Income | -37.8 | -49.7 | -60.4 |
| Diluted Weighted Average Shares | |||
| Basic EPS Including Extraordinary Items | |||
| Diluted EPS Including Extraordinary Items | |||
| Diluted EPS Excluding Extraordinary Items | |||
| Normalised Income Before Taxes | |||
| Normalised Income After Taxes | |||
| Normalised Income Available to Common Shareholders | |||
| Diluted Normalised EPS | -1.43 | -1.87 | -4.25 |